Background: The Benign Prostatic Hyperplasia-Patient Impact Measure (BPH-PIM) is a self-reported quality-of-life questionnaire for measuring the impact of urinary/prostate symptoms on the quality of life of patients with BPH. The aim of the present study was to adapt the original instrument to Spanish (for use in Spain) and to assess the psychometric properties of the new version.
Methods: Linguistic adaptation was performed using the standard processes for establishing conceptual equivalence, and was partially conducted in parallel with original instrument development. Psychometric properties were assessed on a sample of 131 patients with BPH who were receiving treatment with doxazosin gastrointestinal therapeutic system (GITS).
Results: All the standardised items had response rates > 99%; there were no floor or ceiling effects. Reliability in terms of Cronbach's alpha was 0.96 and the intraclass correlation coefficient was 0.97. Construct validity was confirmed by factor analysis. Convergent validity was confirmed in terms of the relationship to the 12-Item Short-Form Health Survey (SF-12) [p < 0.001], Health Utilities Index Mark III (HUI-3) [p < 0.001] and the International Prostate Symptom Score (IPSS) QOL item (p < 0.001). The instrument showed discriminant validity, in terms of IPSS groups (p < 0.001). The instrument was sensitive to change in terms of the correlation of the domain scores of the PIM to improvements in symptom scores (p < 0.001). Significant differences were observed for those who improved > or = 3 points in the IPSS scale (p < 0.001).
Conclusion: A psychometrically valid and conceptually equivalent version of the BPH-PIM questionnaire has been produced in Spanish to be used in Spain in patients with BPH.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2165/00044011-200626020-00005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Asthma-associated prostate enlargement and bladder smooth muscle hypercontractility: unveiling a potential link to LUTS.
BMC Urol
January 2025
Department of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, China.
Background: In male patients, benign prostate hyperplasia (BPH) and overactive bladder (OAB) secondary to BPH are the primary causes of Lower Urinary Tract Symptoms (LUTS). Recent clinical studies have reported an increased risk of LUTS, particularly severe LUTS conditions, in male asthmatic patients. However, the potential link and mechanism remain unclear.
View Article and Find Full Text PDFThe impact of kidney disease on peri-operative outcomes of novel BPH surgeries across the board: a propensity score matched analysis using the ACS-NSQIP database.
World J Urol
January 2025
Division of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon.
Background: Pre-operative kidney disease was shown to impact peri-operative outcomes of endoscopic BPH surgeries. We aim to assess the effect of novel surgical techniques (Laser Enucleation of the Prostate (LEP) and Laser Vaporization of the Prostate (LVP)) compared to Transurethral Resection of Prostate (TURP), on post-operative outcomes stratified based on kidney function.
Methods: The ACS-NSQIP database was reviewed from 2008 to 2021 for 83,020 patients that underwent TURP, LEP, and LVP.
Background: The aim of this study was to explore the clinical application value of serum inflammatory markers in the diagnosis and treatment of benign prostatic hyperplasia (BPH) in elderly men.
Methods: From April 2023 through July 2023, 110 BPH patients and 120 healthy individuals who underwent examinations at our hospital were selected as study subjects. The concentrations of C-reactive protein (CRP), procalcitonin (PCT), serum amyloid A (SAA), complement 3 (C3), and complement 4 (C4) were measured in both groups.
Epidemiological investigation of sex hormones and their metabolism-related gene single nucleotide polymorphisms in patients with benign prostatic hyperplasia complicated with late-onset hypogonadism: a retrospective cohort study.
Int J Surg
December 2024
Department of Urology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, People's Republic of China.
Background: Benign prostatic hyperplasia (BPH) is a common disease in middle-aged and elderly men, and its etiology is not completely clear. Late-onset hypogonadism (LOH) is a relatively common disease in the aging process of men. BPH is often accompanied by varying degrees of LOH, and the pathogenesis and progression of the two diseases are related.
View Article and Find Full Text PDFWater vapor thermal therapy for treatment of lower urinary tract symptoms due to large benign prostatic hyperplasia (≥ 80 g).
World J Urol
January 2025
Department of Urology, AP-HM, North Hospital, Marseille, France.
Introduction: Water vapor thermal therapy (WVTT; REZUM™; Boston, USA) offers symptom relief with reduced risks of complications in patients with lower urinary tract symptoms (LUTS) related to benign prostatic obstruction (BPO). WVTT therapy has been validated in the pivotal study in men with smaller prostates (< 80 cc). Yet, its feasibility for larger prostates (≥ 80 cc) remains underexplored.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!